Cyolo Security Announces Partnership with TD SYNNEX
26.3.2024 15:30:00 EET | Business Wire | Press release
Cyolo, the access company for the industrial enterprise, today announced a new partnership with TD SYNNEX, a leading global distributor and solutions aggregator for the IT ecosystem. The powerful combination of TD SYNNEX’s solution aggregation capabilities and Cyolo’s highly disruptive, distributed secure remote access platform will lead partners to new service lines of revenue. The partnership empowers TD SYNNEX and Cyolo partners to tap into the increased enterprise demand of Secure Remote Access in operational technology (OT), critical infrastructure, cyber physical environments, and their corresponding buying centers.
The partnership with TD SYNNEX serves as the cornerstone of the Cyolo PRO (Privilege Remote Operations) launch. The recently launched Cyolo PRO Platform allows service providers, integrators, OT, IT personnel and other third parties to securely access and safely operate applications, devices and systems in the most critical environments. Cyolo PRO takes secure remote access to new levels with its distributed architecture and its converged security stack capabilities. Cyolo is cloud routed and cloud managed without being cloud hosted. Unlike current technologies such as VPN and SASE that provide users with full access to the network, Cyolo PRO enables secure and privileged access by connecting robustly verified identities to applications with persistent authorization.
“The strategic nature of our TD SYNNEX relationship is a pivotal step in realizing our commitment to delivering future-ready, safe and secure privilege access solutions to the massive industrial market,” said Cyolo’s EVP Corporate Development and OT GM Joe O’Donnell. “Through this collaboration, TD SYNNEX’s partners can bring Cyolo PRO to a broader range of OT, IT and Cyber Physical stakeholders. This increases safety, security and accelerates operational agility. The solution’s capability to seamlessly fit into existing architectures without extensive change management processes is critical in OT environments, as even the slightest network and security change can yield significant consequences.”
This global partnership enables thousands of TD SYNNEX integrators, VARs, MSSPs and Carriers to provide next generation SRA/RPAM (Remote Privilege Access Management) services to their respective customers. Cyolo PRO enables TD SYNNEX partners to address the fast-growing OT and Cyber Physical markets by focusing on crucial elements that increase their clients’ operational agility, improves customers’ security and providing safe yet swift implementations with the lowest cost of change.
"TD SYNNEX is committed to uniting IT solutions that deliver business outcomes today and unlock growth for the future," said Cheryl Day, VP Vendor Acquisition and Global Solutions at TD SYNNEX. "With Cyolo added to our vast portfolio of vendor partners, we're able to enrich the breadth and depth of our offerings so customers can do great things with technology."
To learn more about Cyolo PRO, please visit: https://cyolo.io/product
About Cyolo
Cyolo replaces current SRA implementations with next gen privileged remote operations by connecting verified identities directly to applications with continuous authorization throughout the connection. Purpose-built for deployment in every type of environment, Cyolo PRO combines multiple Remote Privilege Access Management (RPAM) security functions required to mitigate high-risk access, including zero-trust access for users and devices, MFA for the last mile, IdP capabilities, credentials vault, secure file transfer, supervised access, session recording, and much more into a single, cost-effective, easy-to-deploy, and user-friendly platform. For more information visit cyolo.io or follow us on LinkedIn and X.
About TD SYNNEX
TD SYNNEX (NYSE: SNX) is a leading global distributor and solutions aggregator for the IT ecosystem. We’re an innovative partner helping more than 150,000 customers in 100+ countries to maximize the value of technology investments, demonstrate business outcomes and unlock growth opportunities. Headquartered in Clearwater, Florida, and Fremont, California, TD SYNNEX’s 23,000 co-workers are dedicated to uniting compelling IT products, services and solutions from 2,500+ best-in-class technology vendors. Our edge-to-cloud portfolio is anchored in some of the highest-growth technology segments including cloud, cybersecurity, big data/analytics, AI, IoT, mobility and everything as a service. TD SYNNEX is committed to serving customers and communities, and we believe we can have a positive impact on our people and our planet, intentionally acting as a respected corporate citizen. We aspire to be a diverse and inclusive employer of choice for talent across the IT ecosystem. For more information, visit www.TDSYNNEX.com, follow our newsroom or follow us on LinkedIn, Facebook and Instagram.
Copyright 2024 TD SYNNEX Corporation. All rights reserved. TD SYNNEX, the TD SYNNEX Logo, and all other TD SYNNEX company, product and services names and slogans are trademarks of TD SYNNEX Corporation. Other names and trademarks are the property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240326860005/en/
Contact information
Cyolo Media Inquiries
10Fold
cyolo@10Fold.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations30.4.2026 15:05:00 EEST | Press release
Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481) and ELOWEN-2 (NCT07355218), evaluating enpatoran in people living with lupus who experience active skin manifestations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430733656/en/ David Weinreich, Global Head of R&D and Chief Medical Officer “People living with lupus continue to face significant challenges in achieving disease control and are very often affected by itchy, painful and stigmatized skin manifestations,” said David Weinreich, Global Head of R&D, Merck. “With enpatoran, we aim to target the underlying drivers of lupus and redefine how to approach the disease by understanding both visible skin manifestations and systemic activity.” Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor designed to modulate pathways central to lupus-related inflammatio
The LYCRA Company Strengthens Sustainability Leadership, Appoints Alistair Williamson as VP of Product Sustainability30.4.2026 15:00:00 EEST | Press release
The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. In this role, he will guide the company’s next chapter of sustainability strategy and oversee all initiatives aimed at reducing environmental impact across products, operations, and innovation platforms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430942396/en/ The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. Williamson has four decades of experience in textile fibers and apparel, having held commercial, sales, and marketing leadership roles across EMEA, North America, and South Asia. Before joining the predecessor of The LYCRA Company i
Riskified Announces 2026 Titans of Ecommerce Award Winners30.4.2026 15:00:00 EEST | Press release
Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today announced the 2026 Titans of Ecommerce Awards, recognizing outstanding ecommerce leaders who are redefining fraud prevention while driving business growth. The winners are: Titan of Americas: Joseph Chin, Senior Director of Revenue Assurance, Michael Kors Joseph Chin has evolved revenue assurance into a strategic lever for growth at Michael Kors. Deeply knowledgeable in fraud and payments, he maintains a hands-on approach, continually collaborating with Riskified to identify innovative opportunities, optimize performance, and pilot new initiatives. Joseph is highly effective at building internal alignment and securing stakeholder buy-in for new strategies. His leadership shone during Cyber Five, where his close collaboration with Riskified and real-time insights delivered one of Michael Kors’ strongest performance periods. Titan of Europe: Ash Cummings, Ecommerce Fraud Prevention Manager, Gymshark A
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 14:00:00 EEST | Press release
CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which was confirmed by the study’s independent DSMB (Data and Safety Monit
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint ® and BluePrint ® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 14:00:00 EEST | Press release
Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors – a group that typically has favorable outcomes. MammaPrint (MP) identified a High Risk 2 (H2) subset, representing 10% of all patients and 5% of those
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom